Zackary Irani Acquired $3960 Worth of Biomerica, Inc. (BMRA) Shares; GEA GROUP AG (GEAGF) SI Increased By 3.11%

Zackary Irani, Chief Executive Officer of Biomerica Inc is the insider, our team want to tell you for. Mr. Zackary submitted an electronic form with the SEC informing the public of a transaction for 1,000 shares of the public company, the one he is an insider in. At the time of the legal trading transaction, the average market stock price of Biomerica Inc was $4.0, making the total purchase worth $3,960 US Dollars. He also obtained 2,539 shares valued at $10,134 USD in the last 30 days. And, It’s sure Zackary’s trade isn’t going to stay unnoticed as he presently is having in hand 860,039 shares – ( 10.07% of Biomerica Inc’s Market Cap ).

GEA GROUP AG (OTCMKTS:GEAGF) had an increase of 3.11% in short interest. GEAGF’s SI was 2.11M shares in February as released by FINRA. Its up 3.11% from 2.05 million shares previously. It closed at $50.08 lastly. It is down 0.00% since February 6, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 0.25 in Q3 2017. Its up 0.25, from 0 in 2017Q2. It improved, as 2 investors sold Biomerica, Inc. shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 66,682 shares or 11.38% less from 75,249 shares in 2017Q2 were reported. Malaga Cove Cap Ltd Llc invested in 0.03% or 19,000 shares. North Star Invest Mgmt Corp owns 250 shares. Bank & Trust Of America De holds 0% or 3,832 shares. Millennium Mgmt Ltd Llc reported 0% of its portfolio in Biomerica, Inc. (NASDAQ:BMRA). Wells Fargo Mn has 6,500 shares. Panagora Asset Management Inc accumulated 10,077 shares or 0% of the stock.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $33.65 million. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

The stock increased 1.29% or $0.05 during the last trading session, reaching $3.94. About 41,396 shares traded. Biomerica, Inc. (NASDAQ:BMRA) has risen 66.46% since February 6, 2017 and is uptrending. It has outperformed by 49.76% the S&P500.